Trials / Active Not Recruiting
Active Not RecruitingNCT04794010
A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
A German, Nationwide, Prospective, Observational, Multicenter Study in Patients With First-line Nivolumab Plus Ipilimumab Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 825 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to collect real-life data during the early post-market authorization approval period in Germany. The study aims at describing the outcomes, patient characteristics, safety profile, treatment patterns and patient-reported Quality of Life of first-line treatment with nivolumab plus ipilimumab in combination with two cycles of chemo therapy in participants with confirmed stage IV Non-Small Cell Lung Cancer (NSCLC).
Conditions
Timeline
- Start date
- 2020-12-22
- Primary completion
- 2027-12-22
- Completion
- 2027-12-22
- First posted
- 2021-03-11
- Last updated
- 2024-12-12
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04794010. Inclusion in this directory is not an endorsement.